Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Bone Disorders01:29

Bone Disorders

3.9K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.9K
Bone Remodeling01:40

Bone Remodeling

38.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.5K
What is the Skeletal System?01:02

What is the Skeletal System?

53.6K
Overview
53.6K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.9K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.9K
The Functions of the Skeletal System01:22

The Functions of the Skeletal System

4.3K
The most apparent functions of the skeletal system are support, protection, and movement. However, bone tissue also performs several other critical metabolic functions. For one, the bone matrix acts as a reservoir for a number of minerals important to the functioning of the body, especially calcium and phosphorus. These minerals, present in the bone tissue, can be released back into the bloodstream when required. Calcium ions, for example, are essential for muscle contractions and controlling...
4.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Technology in Diabetes: A Year in Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Thyroid Storm With Multiorgan Dysfunction Mimicking Sepsis: Thionamide-Sparing Bridge to Delayed Carbimazole.

Cureus·2026
Same author

Managing diabetic ketoacidosis in special conditions: Difficulties and dilemmas.

World journal of diabetes·2025
Same author

Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects.

Indian journal of endocrinology and metabolism·2025
Same author

Diagnostic approach to rickets: an Endocrine Society of Bengal (ESB) consensus statement.

Annals of pediatric endocrinology & metabolism·2024
Same author

Immunotherapy in type 1 diabetes: Novel pathway to the future ahead.

World journal of diabetes·2024

関連する実験動画

Updated: Sep 9, 2025

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

84.7K

肝臓 骨格 変形 症: 認知 さ れ て い ない 代謝 的 骨 疾患

Subhodip Pramanik1, Rajan Palui2, Sayantan Ray3

  • 1Department of Endocrinology, Neotia Getwel Healthcare Centre, Siliguri 734010, West Bengal, India.

World journal of hepatology
|September 3, 2025
PubMed
まとめ

肝臓骨粗鬆症 (HO) は慢性肝臓疾患 (CLD) の一般的な骨合併症であり,しばしば骨粗鬆症につながります. 管理には個別の評価と リスクファクター緩和が必要ですが 効果的な治療法は まだ研究中です

キーワード:
ビスホスフォネート慢性肝疾患肝臓の骨粗鬆症マネジメント病原性ビタミンD

さらに関連する動画

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics
09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

3.3K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

498

関連する実験動画

Last Updated: Sep 9, 2025

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

84.7K
Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics
09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

3.3K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

498

科学分野:

  • ヘパトロジー
  • 内分泌学
  • 骨の代謝

背景:

  • 肝臓骨粗鬆症 (HO) は,慢性肝臓疾患 (CLD) の頻繁な合併症であり,骨粗鬆症または骨粗鬆症として現れます.
  • 慢性コレスタシスと肝硬変を含む様々なCLDの患者に影響します.
  • 骨密度低下の頻度は,特にCLD患者で増加しています.

研究 の 目的:

  • 慢性肝疾患 (CLD) の肝臓骨粗鬆症 (HO) の最新レビューを提供すること.
  • HOの病原性,管理戦略,現在の治療介入をカバーします.
  • HOの最適な管理と治療法を定義する上でさらなる研究の必要性を強調する.

主な方法:

  • 肝臓骨粗鬆症 (HO) と慢性肝臓疾患 (CLD) に関する既存の文献のレビュー
  • 遺伝的,栄養的,ホルモン的,ライフスタイルの要因を含む多因性の病原性メカニズムの分析.
  • 骨折リスクと骨のミネラル密度に焦点を当てた現在の診断アプローチの評価

主要な成果:

  • HOの病原性は多因性であり,遺伝的要因,ビタミン欠乏,炎症,低子腺症,高ビリルビネミア,および治療法を含む.
  • 管理には骨折リスクと骨のミネラル密度の個別評価が必要です.
  • 予防戦略には,リスクファクターの軽減,低子腺症の治療,健康的なライフスタイル選択の促進が含まれます.

結論:

  • HOの現在の治療は主にビスフォスフォネートを含んでいますが,骨折の減少における有効性は矛盾しています.
  • HOの最終的な管理プロトコルと特定の治療法を確立するには,さらなる研究が不可欠です.
  • HOの理解と治療の改善は,脆弱性骨折を予防し,CLD患者の生活の質を向上させるために不可欠です.